Marijuana Rescheduling: A Physician's Guide to What the DEA's Schedule III Order Means for Patients

By Dr. Erick Kaufman, MD — Medical Director, Doctors of Cannabis Last updated: May 6, 2026

The short answer

On April 22, 2026, the U.S. Department of Justice moved two narrow categories of marijuana from Schedule I to Schedule III: state-licensed medical cannabis and FDA-approved drug products containing marijuana. Everything else — including recreational cannabis, unlicensed products, and synthetically derived THC — remains Schedule I. The change is meaningful, but it is much narrower than the headlines suggest. Here is what every patient should know:

• What was rescheduled: state-licensed medical cannabis and FDA-approved cannabis drug products only
• What was not rescheduled: recreational, unlicensed, and synthetic cannabis products
• Do you still need a medical marijuana card? Yes. State programs and qualifying conditions are unchanged.
• What's next: A DEA hearing scheduled for June 29, 2026 will consider broader rescheduling, and litigation challenges have been threatened.

What is marijuana rescheduling?

Marijuana rescheduling means moving cannabis from one category to another in the federal Controlled Substances Act. The Drug Enforcement Administration (DEA), working with the Department of Health and Human Services and the Food and Drug Administration, sorts controlled substances into five schedules. Each schedule reflects the drug's accepted medical use and its potential for abuse.

Schedule I is the most restrictive category. Drugs in Schedule I are defined as having no accepted medical use and a high risk of abuse. Schedule III is less restrictive. Drugs in Schedule III are defined as having an accepted medical use within a regulated framework and a moderate to low risk of dependence. The April 22, 2026 order moves a narrow slice of cannabis from Schedule I to Schedule III. It does not legalize cannabis, and it does not remove cannabis from federal control.

For background on how the scheduling system works, the DEA maintains a public reference at dea.gov/drug-scheduling.

Has marijuana been rescheduled?

Yes — partially. On April 22, 2026, Acting Attorney General Todd Blanche signed a final order placing two specific categories of cannabis into Schedule III of the Controlled Substances Act, effective immediately:

1. Drug products containing marijuana that have been approved by the FDA — at present, this is a small category that includes Epidiolex.
2. Marijuana that is subject to a state-issued license to manufacture, distribute, or dispense for medical purposes.

The order does not reschedule recreational or adult-use cannabis. It does not reschedule unlicensed cannabis. It does not reschedule synthetically derived THC products. Each of these remains in Schedule I under federal law.

The April 22 order followed an executive order issued on December 18, 2025, which directed the Attorney General to expedite the rescheduling process. The order itself, along with the underlying Department of Justice press release, is published at justice.gov.

A separate DEA administrative hearing — scheduled to begin June 29, 2026 — will consider whether all forms of cannabis, including recreational, should be rescheduled through formal rulemaking. The outcome of that hearing is unknown, and challenges to the April 22 order have been announced by groups opposed to rescheduling.

Is marijuana federally legal now?

No. Rescheduling is not legalization. Cannabis remains a federally controlled substance — just one in a less restrictive category for the narrow set of products covered by the order. The April 22 order itself states that unauthorized growing, possession, and sale of cannabis are still violations of federal law.

The Congressional Research Service has explained that most criminal penalties for cannabis under federal law are written specifically for cannabis. They are not tied to its scheduling status. Those penalties remain in effect after rescheduling. Full federal legalization would require an act of Congress to remove cannabis from the Controlled Substances Act entirely.

For patients, the practical takeaway is simple: state medical cannabis programs continue to operate under state law. Federal protections for state-licensed activity have shifted somewhat. Federal prohibition of recreational cannabis has not.

Do I still need a medical marijuana card?

Yes. State medical cannabis programs are not affected by the federal scheduling change. Your state's qualifying conditions, registration process, physician evaluation requirements, and medical card validity all remain the same.

If you currently hold a valid medical marijuana card, your card continues to function as it did before April 22 in the vast majority of state programs. Some states may adjust administrative processes in response to the federal change; check with your state program for state-specific updates. If you are considering medical cannabis for a qualifying condition, the path to legal access still runs through your state's program — which means a physician evaluation, state registration, and a state-issued card.

This is the most common misconception we are seeing from patients in the days after the rescheduling announcement. Federal scheduling and state medical cannabis programs are two separate legal frameworks. Rescheduling did not replace state programs. It did not create a new federal pathway for patient access. It did not eliminate the need for physician evaluation. If anything, the news has driven a wave of new patients exploring whether they qualify — and the path for them is the same one that existed before April 22.

If you have been managing chronic pain, anxiety, PTSD, insomnia, or another qualifying condition in your state, finding out if you qualify for medical cannabis through a licensed physician is a logical next step.

Doctors of Cannabis connects patients to licensed physicians through our telehealth partner network. You only pay if approved.

See if you qualify in your state →

What is the difference between Schedule I and Schedule III for medical marijuana?

Under federal law, Schedule I substances are defined as having no accepted medical use, a high potential for abuse, and a lack of accepted safety standards for use under medical supervision. Schedule III substances are defined as having an accepted medical use within a regulated framework and a moderate to low potential for physical or psychological dependence.

The practical difference for the narrow category of cannabis now in Schedule III is that the federal government has acknowledged its accepted medical use within a state-licensed framework. This creates a few specific changes — easier conditions for federally registered research, removal of the Section 280E tax penalty for state-licensed cannabis businesses, and expanded federal pathways for state-licensed operators to register with the DEA.

It is important to understand what this regulatory shift does not mean. Schedule III status does not mean the FDA has approved cannabis as a medication. It does not mean cannabis can be prescribed by physicians and dispensed at pharmacies. It does not mean clinical efficacy has been established for any specific condition. The change is regulatory in nature, not clinical. The full set of qualifying conditions, dosing, formulations, and care protocols continues to be determined at the state level and through the physician-patient relationship.

Physician's Take

The phrase "accepted medical use" carries a specific meaning under DEA scheduling that is easy to misread. It is a regulatory classification, not a clinical endorsement. As a board-certified physician who has worked with many medical cannabis patients, I want to be clear about what changed in clinical terms — and what did not.

What changed: the federal government now acknowledges that cannabis has accepted medical use within state-regulated frameworks. This may make it easier for primary care physicians outside cannabis programs to engage with the topic, and it removes some of the stigma patients have faced. Research access has improved. Industry economics have shifted.

What did not change: the clinical evidence base for medical cannabis. Rescheduling is not a substitute for FDA approval, which requires rigorous clinical trial data on specific products for specific conditions. The cannabis available in state dispensaries has not been through that process. As physicians, we still recommend medical cannabis based on a careful evaluation of your qualifying condition, your other medications, and your overall health — and we still operate within state medical board guidelines that vary considerably.

If you are bringing this news up with your primary care doctor, expect a mixed reception. Some physicians will be more comfortable discussing cannabis now that the federal classification has shifted. Others will remain cautious, and they have legitimate reasons to do so. The right next step for most patients has not changed: an evaluation with a physician who is experienced in your state's medical cannabis program, who can review your full clinical picture, and who can determine whether certification is appropriate.

— Dr. Erick Kaufman, MD

What didn't change after rescheduling

Most coverage of the rescheduling order has emphasized what changed. As a physician advising patients, I think it is at least as important to be clear about what did not change. Several federal frameworks that affect cannabis patients continue to operate exactly as they did before April 22.

• Federal drug testing rules. Federal employee drug testing requirements and Department of Transportation safety-sensitive testing rules are unchanged. A medical card does not protect a patient from a positive cannabis test in these contexts.

• VA cannabis policy. Veterans Health Administration Directive 1315 continues to prohibit VA physicians from recommending or completing state medical cannabis paperwork. Veterans who want medical cannabis must continue to seek physician evaluations outside the VA system.

• Interstate transport. Carrying cannabis across state lines remains a federal crime, regardless of state cards or state legality at either origin or destination. The April 22 order did not address interstate commerce.

• Federal employment protections. There is no federal employment protection for medical cannabis patients. Some states provide limited protections; many do not. Workplace policies continue to be governed by employer rules and state law.

• Pharmacy access. Cannabis is not dispensed through pharmacies. Schedule III drugs that are FDA-approved (such as Tylenol with codeine and certain anabolic steroids) move through pharmacies because they have completed FDA approval. Cannabis itself has not. State medical cannabis access continues exclusively through state-licensed dispensaries.

• Health insurance coverage. Insurance reimbursement requires FDA-approved indications. Rescheduling does not provide that. Patients should expect to continue paying out of pocket for medical cannabis for the foreseeable future.

• Federal criminal penalties for unauthorized possession. Most federal criminal statutes for cannabis are written specifically for cannabis rather than tied to its schedule. Those penalties remain in effect, as the Congressional Research Service has documented in its legal analysis.

• Background checks, child custody, housing, and immigration. Many collateral consequences of cannabis use under federal frameworks — including HUD housing rules and federal immigration consequences — flow from the underlying federal classification rather than the schedule number. Rescheduling does not resolve these.

The honest summary is that rescheduling improved the landscape for state-licensed cannabis operators, removed a tax penalty, expanded research access, and validated state programs at the federal level. It did not give patients new federal protections, did not make cannabis a prescribable medication, and did not eliminate most of the legal frictions patients have encountered for years.

Will medical cannabis be available at my pharmacy now?

No. Pharmacies dispense FDA-approved drugs. Cannabis itself has not been through FDA approval — only specific drug products derived from cannabis, such as Epidiolex, have. Those approved products do move through pharmacies and have for years.

The cannabis available through state medical programs is not FDA-approved and will continue to be distributed through state-licensed dispensaries under state regulatory frameworks. The April 22 order does not change this. The New York Office of Cannabis Management has confirmed this directly in its public guidance on Schedule III: "Cannabis would not move into pharmacies. Pharmacies may dispense only FDA-approved drugs."

What does rescheduling mean for medical cannabis research?

Research access is the area where rescheduling produces the clearest, most immediate improvement. Schedule I status has long been a significant barrier to clinical cannabis research in the United States. Researchers needed specialized DEA registrations, faced strict requirements about product sourcing, and worked under restrictions that complicated meaningful clinical trials.

Schedule III status removes several of these barriers. Researchers can engage in cannabis research under standard Schedule III registration requirements, can source product from state-licensed entities with valid federal registration, and can pursue clinical questions that were previously difficult to study. Universities, hospitals, and research institutions that had concerns about federal funding implications now have more clarity.

What this does not mean: a flood of clinical trials with immediate results. Investigational New Drug applications are still required for human clinical research with cannabis, and meaningful clinical trial data takes years to generate, peer-review, and publish. Patients should expect a gradual expansion of the cannabis research literature over the coming years, not an overnight shift in clinical recommendations. Pharmacy Times offered a useful clinical analysis of the implications shortly after the order.

What about the cannabis industry — and will prices change?

The most consequential industry change is the elimination of Section 280E for state-licensed medical cannabis businesses. Under Section 280E, businesses dealing in Schedule I or II controlled substances cannot deduct ordinary business expenses from their federal taxes. This created an effective tax burden that significantly raised costs for state-licensed dispensaries. Removal of 280E for the medical cannabis category will improve the economics of state-licensed businesses.

Whether those savings reach patients in the form of lower prices is a separate question. Pricing depends on state-level competition, dispensary market structure, regulatory choices, and the specific economics of each state program. Some states may see modest price improvements over time. Others may not. Patients should not expect immediate price changes at their dispensary.

Banking access for cannabis businesses may improve as the industry stabilizes financially, which could expand patient payment options over time. As of the April 22 order, federal banking guidance for cannabis businesses has not formally changed, but practical conditions are likely to evolve.

What's next? The June 29, 2026 hearing and pending challenges

The April 22 order is the middle of a longer story, not the end. Several developments will shape the federal cannabis landscape over the coming months.

The June 29 DEA hearing. A formal administrative hearing has been scheduled to consider whether all forms of cannabis — including recreational — should be rescheduled through standard rulemaking. The hearing builds on a proposed rule from 2024 and is expected to conclude by mid-July 2026. The outcome is genuinely uncertain. A broader rescheduling could shift the landscape further; a narrow ruling could leave the April 22 order as the final word for the foreseeable future.

Litigation challenges. Smart Approaches to Marijuana, an organization opposed to rescheduling, has announced plans to sue. Other challenges may follow. Federal courts will weigh in on whether the April 22 order followed required procedures and whether its scope is consistent with the Controlled Substances Act. Litigation could delay implementation or reshape the order.

State-level adjustments. Some states are reviewing their medical cannabis statutes in light of the federal change. Most state programs are expected to continue operating largely as they have. Patients in states with active legislative sessions should watch for changes specific to their state's qualifying conditions, registration requirements, and patient protections.

FDA enforcement posture. The FDA has not yet issued formal guidance on the rescheduling order. The agency's posture toward cannabis-derived products marketed as foods, supplements, or unapproved drugs has historically been one of selective enforcement. The legal analysis from Gibson Dunn and Foley & Lardner provides operator-focused detail for readers who want the deep regulatory picture.

This section will be updated after the June 29 hearing and as litigation develops.

How Doctors of Cannabis helps patients navigate medical cannabis access

State medical cannabis programs are real, and they work — but they are not always easy to navigate. Qualifying conditions vary by state. Registration portals are inconsistent. Many primary care physicians do not feel comfortable discussing cannabis evaluations, and getting an appointment with a physician who does can take weeks. Even after rescheduling, the practical experience for many patients has not improved.

Doctors of Cannabis was founded by Dr. Erick Kaufman in 2018 to give patients a clearer path. We are a physician-led education and patient referral platform. Our model is built around three principles:

• Physician-led evaluations. Patient evaluations are conducted by licensed physicians experienced in medical cannabis. Where state programs have particularly burdensome administrative requirements, our Application Assistance Program pairs that clinical evaluation with non-medical administrative support from trained partners.
• Education first. We focus on helping patients understand whether they qualify, what their state program requires, and what to expect from a physician evaluation. The goal is informed decisions, not pressure to certify.
• You only pay if approved. If the evaluating physician does not certify you, you receive a full refund. This is the core differentiator of our model and is unchanged by rescheduling.

The process is straightforward: connect online with a licensed physician through our telehealth partner network, complete a medical evaluation for your state's qualifying conditions, and — if the evaluating physician determines you qualify — they will submit certification to your state registry.

For patients in states where the application process is particularly burdensome, our Application Assistance Program (AAP) is being developed to provide non-medical administrative support for state portal navigation. We will share more on AAP availability as it rolls out.

If you have been considering medical cannabis for a qualifying condition, finding out whether you qualify through a licensed physician is the next concrete step. Rescheduling did not change the path to legal access — it still runs through your state program and a physician evaluation.

Doctors of Cannabis connects patients to licensed physicians through our telehealth partner network. You only pay if approved.

Find out if you qualify in your state →

A final note from Dr. Kaufman

The April 22 rescheduling is meaningful, but it is narrower than the headlines suggest, and it does not replace the role of state medical cannabis programs or physician evaluation. If you have been considering whether medical cannabis fits into your care, the rules for getting there have not changed. The path still runs through your state program and a licensed physician's evaluation. Doctors of Cannabis is an education and patient referral platform — we are not a medical clinic, and the physician evaluations our patients receive are conducted by independent licensed physicians through our telehealth partner network. We will continue to update this page as the June 29 hearing, pending litigation, and state-level developments unfold.

Frequently asked questions

Did Trump reschedule marijuana? Yes — partially. The rescheduling was directed by President Trump's executive order of December 18, 2025, which instructed the Attorney General to expedite the rescheduling process. The final order was then issued on April 22, 2026 by Acting Attorney General Todd Blanche, on behalf of the Department of Justice and the DEA. The order rescheduled state-licensed medical cannabis and FDA-approved cannabis drug products only. Recreational, unlicensed, and synthetic cannabis remain Schedule I.

Is marijuana a Schedule 3 drug now? Two narrow categories of cannabis are now Schedule III: state-licensed medical cannabis and FDA-approved cannabis drug products. All other cannabis — recreational, unlicensed, and synthetic THC — remains Schedule I.

Does rescheduling marijuana to Schedule III legalize recreational use? No. Recreational cannabis remains Schedule I under federal law. The April 22 order only addressed state-licensed medical cannabis and FDA-approved products.

What happens now that marijuana is Schedule 3? For state-licensed cannabis businesses: Section 280E tax penalties are removed and a new federal DEA registration pathway is available. For research: federal restrictions are reduced. For patients: state programs and qualifying conditions are unchanged, and a state-issued medical card is still required for legal access.

When will marijuana be Schedule 3 for everyone? Unknown. A DEA hearing scheduled for June 29, 2026 will consider broader rescheduling. The outcome will determine whether all cannabis moves to Schedule III through formal rulemaking.